STOK
BEARISH
$37.27
Live
Stoke Therapeutics, Inc. · NASDAQ
Target $45.1
(+21.0%)
$7.48
52W Range
$40.22
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 20, 2026
Market cap
$2.2B
P/E
N/A
ROE
-2.4%
Profit margin
-3.7%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
STOK exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health. Despite a massive 1-year price surge of 384.7%, the company is facing a catastrophic revenue decline of 93.8% and significant operating losses. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish insider activity, with executives selling $3.75M in shares. The current valuation is speculative, unsupported by earnings or growth metrics.
Key Strengths
Very strong liquidity with a Current Ratio of 5.28
Negligible debt levels (Debt/Equity of 0.01)
Strong analyst support with a 'Strong Buy' consensus
Significant 1-year price momentum (+384.7%)
High gross margins (100%) typical of pre-commercial biotech
Key Risks
Severe revenue collapse (-93.8% YoY)
Extremely weak Piotroski F-Score (2/9)
Deeply negative operating margins (-4382.24%)
Bearish insider sentiment with 12 sell transactions and 0 buys
High valuation multiples (P/S of 11.95) despite shrinking revenue
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
20
15
40
30
0
AI Verdict
Speculative/High Risk
Key drivers: Revenue collapse, Low Piotroski score, Insider selling, Lack of profitability
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- P/S ratio of 11.95 is high for declining revenue
- P/B of 6.23 indicates a significant premium over book value
- No Graham Number available due to lack of earnings
Future
15/100
Ref Growth rates
Positives
- High analyst target price ($45.10)
Watchpoints
- Revenue growth is -93.80%
- Year-over-Year EPS growth is -438.9%
Past
40/100
Ref Historical trends
Positives
- Exceptional 1-year price return (+384.7%)
- 3-year growth of +332.9%
Watchpoints
- Poor earnings surprise track record (1/4 beats in last 4 quarters)
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low Debt/Equity (0.01)
- High Current Ratio (5.28)
Watchpoints
- Piotroski F-Score of 2/9 indicates weak financial health
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$37.27
Analyst Target
$45.1
Upside/Downside
+21.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for STOK and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
Primary
|
+22.0% | +332.9% | +384.7% | +11.2% | +20.1% | +8.6% |
|
DAWN
Day One Biopharmaceuticals, Inc.
Peer
|
-8.7% | +69.0% | +205.7% | +189.6% | +0.6% | +0.1% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
PAHC
Phibro Animal Health Corporation
Peer
|
+144.3% | +265.7% | +224.4% | +40.4% | +2.6% | -8.8% |
|
ACHC
Acadia Healthcare Company, Inc.
Peer
|
-61.4% | -66.0% | -16.5% | +8.2% | +51.5% | -8.2% |
STO
Stoke Therapeutics, Inc.
Primary
5Y
+22.0%
3Y
+332.9%
1Y
+384.7%
6M
+11.2%
1M
+20.1%
1W
+8.6%
DAW
Day One Biopharmaceuticals, Inc.
Peer
5Y
-8.7%
3Y
+69.0%
1Y
+205.7%
6M
+189.6%
1M
+0.6%
1W
+0.1%
BHC
Bausch Health Companies Inc.
Peer
5Y
-78.1%
3Y
-29.4%
1Y
-24.3%
6M
-12.7%
1M
-17.7%
1W
-15.3%
PAH
Phibro Animal Health Corporation
Peer
5Y
+144.3%
3Y
+265.7%
1Y
+224.4%
6M
+40.4%
1M
+2.6%
1W
-8.8%
ACH
Acadia Healthcare Company, Inc.
Peer
5Y
-61.4%
3Y
-66.0%
1Y
-16.5%
6M
+8.2%
1M
+51.5%
1W
-8.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-11.73
PEG Ratio
N/A
P/B Ratio
6.23
P/S Ratio
11.95
EV/Revenue
10.43
EV/EBITDA
-102.23
Market Cap
$2.2B
Profitability
Profit margins and return metrics
Profit Margin
-3.73%
Operating Margin
-4382.24%
Gross Margin
100.0%
ROE
-2.37%
ROA
-3.73%
Growth
Revenue and earnings growth rates
Revenue Growth
-93.8%
Earnings Growth
N/A
Q/Q Revenue Growth
-93.8%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
5.28
Strong
Quick Ratio
5.05
Excellent
Cash/Share
$4.81
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-4382.2%
Net Margin
-4132.2%
Total Assets
$0.4B
Liabilities
$0.1B
Equity
$0.4B
Debt/Equity
0.19x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-03-16
$-0.97
-31.8% surprise
2025-11-04
$-0.65
-13.2% surprise
2025-08-12
$-0.4
+25.5% surprise
Healthcare Sector Comparison
Comparing STOK against 470 companies in the Healthcare sector
(26 bullish, 143 neutral, 301 bearish)
Return on Equity (ROE)
-2.37%
This Stock
vs
-97.91%
Sector Avg
-97.6%
(Below Avg)
Profit Margin
-3.73%
This Stock
vs
-16.16%
Sector Avg
-76.9%
(Weaker)
Debt to Equity
0.01
This Stock
vs
3.0
Sector Avg
-99.6%
(Less Debt)
Revenue Growth
-93.8%
This Stock
vs
142.9%
Sector Avg
-165.6%
(Slower)
Current Ratio
5.28
This Stock
vs
4.65
Sector Avg
+13.6%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
|
BEARISH | $2.2B | - | -2.4% | -3.7% | $37.27 | |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
NEUTRAL | $2.22B | - | -22.7% | -67.8% | $21.46 | Compare |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | Compare |
|
PAHC
Phibro Animal Health Corporation
|
NEUTRAL | $2.18B | 23.84 | 31.8% | 6.3% | $53.88 | Compare |
|
ACHC
Acadia Healthcare Company, Inc.
|
BEARISH | $2.17B | - | -41.0% | -33.3% | $23.52 | Compare |
STOK
Stoke Therapeutics, Inc.
BEARISH
Mkt Cap
$2.2B
P/E
-
ROE
-2.4%
Price
$37.27
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | TICHO BARUCH S | Officer | Sale | 1,838 | $60,029 |
| 2026-03-20 | ALLAN JONATHAN | General Counsel | Sale | 9,293 | $313,038 |
| 2026-03-19 | TICHO BARUCH S | Officer | Sale | 14,311 | $456,835 |
| 2026-03-19 | TICHO BARUCH S | Officer | Option Exercise | 1,365 | $2,989 |
| 2026-03-18 | HOITT JASON | Officer | Sale | 3,712 | $119,311 |
| 2026-03-18 | LEGGETT THOMAS | Chief Financial Officer | Sale | 4,578 | $147,145 |
| 2026-03-18 | ALLAN JONATHAN | General Counsel | Sale | 8,895 | $285,901 |
| 2026-03-13 | LEVIN ARTHUR A. | Director | Sale | 605 | $22,264 |
| 2026-03-13 | KAYE EDWARD M | Director | Stock Award | 61,750 | - |
| 2026-03-13 | HOITT JASON | Officer | Stock Award | 10,000 | - |
| 2026-03-13 | LEGGETT THOMAS | Chief Financial Officer | Stock Award | 14,750 | - |
| 2026-03-13 | TICHO BARUCH S | Officer | Stock Award | 33,850 | - |
| 2026-03-13 | ALLAN JONATHAN | General Counsel | Stock Award | 25,475 | - |
| 2026-03-10 | TZIANABOS ARTHUR | Officer and Director | Sale | 4,355 | $174,214 |
| 2026-03-10 | TZIANABOS ARTHUR | Officer and Director | Option Exercise | 3,955 | $32,945 |
TICHO BARUCH S
Officer
2026-04-01
1,838 shares
·
$60,029
ALLAN JONATHAN
General Counsel
2026-03-20
9,293 shares
·
$313,038
TICHO BARUCH S
Officer
2026-03-19
14,311 shares
·
$456,835
TICHO BARUCH S
Officer
2026-03-19
1,365 shares
·
$2,989
HOITT JASON
Officer
2026-03-18
3,712 shares
·
$119,311
LEGGETT THOMAS
Chief Financial Officer
2026-03-18
4,578 shares
·
$147,145
ALLAN JONATHAN
General Counsel
2026-03-18
8,895 shares
·
$285,901
LEVIN ARTHUR A.
Director
2026-03-13
605 shares
·
$22,264
KAYE EDWARD M
Director
2026-03-13
61,750 shares
HOITT JASON
Officer
2026-03-13
10,000 shares
LEGGETT THOMAS
Chief Financial Officer
2026-03-13
14,750 shares
TICHO BARUCH S
Officer
2026-03-13
33,850 shares
ALLAN JONATHAN
General Counsel
2026-03-13
25,475 shares
TZIANABOS ARTHUR
Officer and Director
2026-03-10
4,355 shares
·
$174,214
TZIANABOS ARTHUR
Officer and Director
2026-03-10
3,955 shares
·
$32,945
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
10 analysts
Canaccord Genuity
2026-03-20
Buy
Buy
BTIG
2026-03-19
Buy
Buy
Wedbush
2026-03-18
Outperform
Outperform
Chardan Capital
2026-03-18
Buy
Buy
Wedbush
2026-03-17
Outperform
Outperform
Needham
2026-03-17
Buy
Buy
Wolfe Research
2026-02-24
Outperform
Wedbush
2026-01-12
Outperform
Outperform
Chardan Capital
2026-01-05
Buy
Buy
Canaccord Genuity
2026-01-05
Buy
Buy
Past News Coverage
Recent headlines mentioning STOK from our newsroom.
Newest → oldest
No matching news yet.